Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial
Patrick N. A. Harris(The University of Queensland), David L. Paterson(The University of Queensland), Andrew J. Stewardson(Austin Health), Emma S. McBryde(The University of Queensland), Paul R. Ingram(Fiona Stanley Hospital), Jason A. Roberts(Université de Montpellier), Benjamin A. Rogers(Monash University), Jonathan R. Iredell(The University of Sydney), Jeffrey Lipman(The University of Queensland), Sanjoy K. Paul(University of Leicester), Eugene Athan(Barwon Health), Anton Y. Peleg(Discovery Institute), Tiffany Harris‐Brown(The University of Queensland), Peter Baker(The University of Queensland), Spiros Miyakis(UNSW Sydney)
Cited by 73
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Antimicrobial Resistance in ESKAPE Pathogens
|Clinical Microbiology Reviews|2020|2k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
|Clinical Infectious Diseases|2014|1.1k
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
|Intensive Care Medicine|2020|1.1k